Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 21 strange trades.

Benzinga

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 10 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.

Benzinga

Eli Lilly Whale Trades For August 11

Benzinga

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Benzinga

2 Stocks That Could Be Long-Term Winners for Investors

With the economy reporting two consecutive quarters of GDP decline, many analysts believe that the economy has already entered a recession. During periods of market uncertainty, investors should look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Pfizer…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

StockNews.com

Is Biotech Ready for Another Bull Run? 3 Stocks to Get in Ahead of the Crowd

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

StockNews.com

2 Biotech Stocks Crushing It During the Market Crash

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

StockNews.com

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 14 strange trades.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

Benzinga

This Is What Whales Are Betting On Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 17 strange trades.

Benzinga

LLY's New Drug Lineup Looks Promising For Investors

Eli Lilly and Company’s (LLY) new drug line-up is expected to generate higher revenues and earnings. Also, LLY’s robust earnings, favorable analyst estimates, and higher-than-industry profitability make it a promising investment option. Read on….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Stocks Upgraded To "Strong Buy" Last Week

Investors’ concerns over the impending interest rate hikes are expected to keep the markets highly volatile in the near term. Therefore, it could be wise to invest in fundamentally-sound stocks Group 1 Automotive (GPI), Eli Lilly and Company (LLY), nVent Electric (NVT), Primo Water (PRMW), and Sanmina (SANM) that are…

Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,000 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 5.21% on an annualized basis producing an average annual return of 11.42%. Currently, Eli Lilly has a market capitalization of $273.33 billion.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 35 strange trades.

StockNews.com

3 Growth Stocks to Buy if You Think Inflation Has Peaked

A slightly lower consumer price index in April and expectations of a flat or lower CPI in May indicate inflation may have peaked. Yesterday, the major U.S. stock indices increased slightly as leading growth stocks rallied. Given this backdrop, we think it could be wise to invest in the shares…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Benzinga

Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American Diabetes Association. At 28 weeks, participants taking Mounjaro (N=45) had significantly greater reductions in weight and fat mass compared to Novo Nordisk A/S's (NYSE:NVO) injectable Ozempic…

Benzinga

Looking At Eli Lilly's Recent Whale Trades

Benzinga

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Benzinga

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Benzinga

Why Eli Lilly Shares Are Trading Higher Today

The FDA approved Eli Lilly And Co's (NYSE:LLY) injected drug tirzepatide, which has the brand name Mounjaro (tirzepatide), to help improve blood sugar control in adults with type 2 diabetes. The approval covers tirzepatide as an adjunct to diet and exercise. As the first and only FDA-approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1…

Benzinga

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

1 … 11 12 13 14

People

Dipanjan BanchurSince

722 stories

Mounjaro

42 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

BristolMyers Squibb Company

95 stories

European Medicines Agency

76 stories

INCY

70 stories

Medical – Pharmaceuticals

69 stories

Johnson

65 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.